Are Peptides Legal in Florida? (2026)

By the Peptide Bureau Research Team Regulation Reviewed by the Peptide Bureau Research Team on 28 September 2026

Not legal advice. This page summarises public statutes, board statements and enforcement records for Florida as of 28 September 2026, for general information. It is not a legal opinion. Laws change; check the linked sources or a licensed Florida attorney before relying on anything here. Compounds are discussed in a research context only.

Short answer. There is no Florida statute that bans buying or possessing research peptides as a category. Federal law does the regulating: selling an unapproved peptide for human use is a federal violation by the seller, and human growth hormone has its own federal statute. The Bureau found no peptide that Florida has scheduled or banned on its own. The Florida Board of Pharmacy has taken a position on compounded semaglutide or tirzepatide, which matters if you are looking at a clinic or telehealth prescription rather than a research vial. Verified against the sources listed at the bottom on 28 September 2026. Not legal advice.

Florida at a glance

State controlled-substances law: Fla. Stat. ch. 893 (Florida Comprehensive Drug Abuse Prevention and Control Act); schedules at § 893.03 (flsenate.gov)
Human growth hormone under state law: Not separately scheduled; the federal statute 21 U.S.C. § 333(e) applies (Fla. Stat. § 893.03; § 458.331(1)(ee)) (leg.state.fl.us)
Research peptides scheduled by the state: None found
Board of Pharmacy on compounded GLP-1s: No GLP-1-specific Board of Pharmacy statement was found. Board rule 64B16-27.797 (standards of practice for compounding sterile products) was amended effective 2 February 2025 and ties Florida sterile compounding to section 503A of the federal act (2025-02-02) (flrules.org)
Medical board on peptide prescribing: No statement located
GLP-1 by telehealth: Yes. Fla. Stat. § 456.47 says a telehealth provider is not required to research a patient's medical history or conduct a physical examination if the evaluation is sufficient; out-of-state providers may register to treat Florida patients by telehealth but may not open an office or see patients in person. (leg.state.fl.us)
State-level enforcement, 2023 to 2026: None found
Last verified: 28 September 2026, confidence high

The federal rules that apply in Florida, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Florida:

Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Florida. The PCAC vote page has every tally.
GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Florida law adds

Florida's controlled-substances law (Fla. Stat. ch. 893 (Florida Comprehensive Drug Abuse Prevention and Control Act); schedules at § 893.03) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (flsenate.gov)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on Florida's schedules or in a Florida-specific ban as of September 2026. That is the position in most states.

Human growth hormone

Growth hormone and gonadotropin do not appear in Florida's schedules. Separately, § 458.331(1)(ee) makes it a disciplinary offence for a physician to prescribe or supply growth hormones, testosterone or its analogs, hCG or other hormones for muscle building or to enhance athletic performance. (Fla. Stat. § 893.03; § 458.331(1)(ee)) (leg.state.fl.us)

Compounded semaglutide and tirzepatide

2025-02-02. No GLP-1-specific Board of Pharmacy statement was found. Board rule 64B16-27.797 (standards of practice for compounding sterile products) was amended effective 2 February 2025 and ties Florida sterile compounding to section 503A of the federal act. (flrules.org)

This is about licensed pharmacies and prescriptions. It does not make a research vial legal or illegal; those sit under the federal unapproved-drug rules described above.

Clinics, medspas and prescribers

No Florida medical board guidance specific to peptide therapy was located. A Florida prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in Florida

Fla. Stat. § 499.03 makes possessing any new drug or prescription drug without a valid prescription a second-degree misdemeanor (a third-degree felony with intent to sell), which can reach unapproved peptides held for human use; no scheduling applies to BPC-157 and the other research peptides. (leg.state.fl.us)

Ordering from a vendor in another state. Almost every research-peptide order into Florida is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes. Fla. Stat. § 456.47 says a telehealth provider is not required to research a patient's medical history or conduct a physical examination if the evaluation is sufficient; out-of-state providers may register to treat Florida patients by telehealth but may not open an office or see patients in person. (leg.state.fl.us) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Florida law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Enforcement in Florida

The Bureau found no Florida-level action against a peptide seller, clinic or compounded-GLP-1 seller between 2023 and September 2026. Federal actions apply regardless of state; the enforcement tracker lists them.

Editor's note. SB 860 (2026), which would have required sourcing documentation for compounded weight-loss drugs, died in committee on 13 March 2026. Several of the 2026 FDA warning letters went to Florida-based research-peptide sellers, and Connecticut's Triggered Brand defendant was Florida-based, but no Florida attorney general or Board of Medicine action against a peptide seller was located.

Frequently asked questions

Is BPC-157 legal in Florida?

Florida has not scheduled BPC-157, so possessing it is not a Florida offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Florida?

Yes. Fla. Stat. § 456.47 says a telehealth provider is not required to research a patient's medical history or conduct a physical examination if the evaluation is sufficient; out-of-state providers may register to treat Florida patients by telehealth but may not open an office or see patients in person. The Florida Board of Pharmacy position on compounded versions: No GLP-1-specific Board of Pharmacy statement was found. Board rule 64B16-27.797 (standards of practice for compounding sterile products) was amended effective 2 February 2025 and ties Florida sterile compounding to section 503A of the federal act.

Is HGH legal in Florida?

Only with a valid prescription for an approved use. Florida does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

Every Florida fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.